Bloomberg
Lilly Buying Spree Surpasses $32B
Wednesday, November 18, 2026
Eli Lilly agreed to acquire Calytrix Bio in a deal valued at up to 1.5 billion dollars, according to Bloomberg. The acquisition is part of Lilly's broader spending on deals totaling 32 billion dollars in 2026. Lilly has stated it is using the acquisitions to expand its cancer and immunology businesses.
Original reporting:
- Bloomberg — Lilly Buying Spree Surpasses $32B
